Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ, .
A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease.
Sleep. 2003 Nov 1;26(7):893-901.
PubMed.
It's too early to say this is a final failure just because of a one-time experiment, However, if we ascribe insomina of AD patients only to their shortness of melatonin, it should be unbelieveable. Until now, we do not know the exact cause(s) and meachanism of AD. Only when we clarify them can we say whether melatonin is helpful or not for AD patients.
Dosages of 2.5 and 3 milligrams of melatonin produce short sleep and nightmares followed by drowsiness. The experiment should be repeated with more physiological dosages of 0.1 or 0.2 milligrams.
References: The Hormone Handbook, by Thierry Hertoghe MD
Comments
Okayama university Medical shool
It's too early to say this is a final failure just because of a one-time experiment, However, if we ascribe insomina of AD patients only to their shortness of melatonin, it should be unbelieveable. Until now, we do not know the exact cause(s) and meachanism of AD. Only when we clarify them can we say whether melatonin is helpful or not for AD patients.
View all comments by wuhua xuHillman Cancer Center
Every try is a necessary step to best treatment.
View all comments by Jun Xusee www.longevinst.org/cur.htm
Dosages of 2.5 and 3 milligrams of melatonin produce short sleep and nightmares followed by drowsiness. The experiment should be repeated with more physiological dosages of 0.1 or 0.2 milligrams.
References:
The Hormone Handbook, by Thierry Hertoghe MD
Make a Comment
To make a comment you must login or register.